Literature DB >> 3024028

Diazepam attenuates the antagonism of haloperidol against apomorphine-induced stereotypic behavior after subchronic but not acute treatment in rats.

V Fuchs, H Coper, S Strauss, H Rommelspacher.   

Abstract

Apomorphine-induced stereotypic behavior was investigated in rats treated with diazepam or haloperidol and with the combination of both drugs in a one day trial or subchronically. The drugs were administered via the drinking water. Diazepam dose-dependently reduced apomorphine stereotypies after the subchronic (6 days) but not after the acute treatment. Haloperidol suppressed apomorphine-induced stereotypic behavior dose-dependently after acute as well as after subchronic administration apparently without the development of tolerance. This discrepancy to other studies may be explained by the concomitant increase in maximum number of D2-receptors in the striatum. The apomorphine antagonistic effect of haloperidol was attenuated when the neuroleptic was administered subchronically in combination with the benzodiazepine. This finding was unexpected since both drugs reduced apomorphine-induced stereotypic behavior when administered alone. The further increase in maximum number of D2-receptors due to combined treatment with low doses of diazepam, suggesting a sort of "over adaptation", possibly explains the haloperidol-antagonistic action of diazepam in the behavioral experiments. Binding studies on dopamine (D1), 5-hydroxytryptamine (5-HT2) and benzodiazepine receptors revealed that modification of the apomorphine-induced stereotypies by the combined treatment with haloperidol and diazepam cannot be explained by interactions of the drugs at the level of the D1, 5-HT2 or benzodiazepine-receptors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3024028     DOI: 10.1007/bf00505812

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  20 in total

1.  GABAergic modulation of benzodiazepine binding site sensitivity.

Authors:  J F Tallman; J W Thomas; D W Gallager
Journal:  Nature       Date:  1978-07-27       Impact factor: 49.962

2.  [Effect of neuroleptic agents in the chronic pharmacological experiment].

Authors:  G Stille; H Lauener
Journal:  Arzneimittelforschung       Date:  1974-09

3.  Functional role of the nigro-neostriatal dopamine neurons.

Authors:  N E Andén; A Dahlström; K Fuxe; K Larsson
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1966

4.  gamma-Aminobutyric acid (GABA) receptor stimulation. III. Effect of progabide (SL 76002) on norepinephrine, dopamine and 5-hydroxytryptamine turnover in rat brain areas.

Authors:  B Scatton; B Zivkovic; J Dedek; K G Lloyd; J Constantinidis; R Tissot; G Bartholini
Journal:  J Pharmacol Exp Ther       Date:  1982-03       Impact factor: 4.030

5.  Effect of apomorphine and gabaergic drugs in monkeys pretreated with haloperidol.

Authors:  N Bjørndal; J Gerlach; D E Casey; E Christensson
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

6.  Pharmacology of the GABAergic system: effects of progabide, a GABA receptor agonist.

Authors:  G Bartholini
Journal:  Psychoneuroendocrinology       Date:  1984       Impact factor: 4.905

7.  Dopamine receptor binding of 3H-ADTN (2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene) regulated by guanyl nucleotides.

Authors:  I Creese; S H Snyder
Journal:  Eur J Pharmacol       Date:  1978-08-15       Impact factor: 4.432

8.  The chemical basis for the blockade of the D-1 dopamine receptor by SCH 23390.

Authors:  Y Itoh; M Beaulieu; J W Kebabian
Journal:  Eur J Pharmacol       Date:  1984-04-13       Impact factor: 4.432

9.  Benzodiazepine interactions with GABA receptors.

Authors:  W Haefely
Journal:  Neurosci Lett       Date:  1984-06-29       Impact factor: 3.046

10.  gamma-Aminobutyric acid (GABA) receptor stimulation. I. Neuropharmacological profiles of progabide (SL 76002) and SL 75102, with emphasis on their anticonvulsant spectra.

Authors:  P Worms; H Depoortere; A Durand; P L Morselli; K G Lloyd; G Bartholini
Journal:  J Pharmacol Exp Ther       Date:  1982-03       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.